NCT05949944进行中（未招募）1 期
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）
Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2023年8月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
- 试验地点
- 2
- 主要终点
- Dose-limiting toxicity (DLT, Phase Ib)
研究概览
简要总结
This phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed PTCL, including peripheral T-cell lymphoma non-specific type (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), enteropathy related T-cell lymphoma and liver spleen T-cell lymphoma;
- •Has not received anti-tumor treatment in the past;
- •There must be at least one evaluable lesion/measurable lesion according to the 2014 Lugano Lymphoma Evaluation Criteria. An evaluable lesion is defined as a lymph node or extra-nodal local lesion that shows increased uptake of 18FDG on PET-CT (higher than the liver), with lesion characteristics consistent with lymphoma manifestations. A measurable lesion is defined as a nodule with a longest diameter of >15mm or an extra-nodal lesion with a longest diameter of >10mm, accompanied by increased uptake of 18FDG. Exclusion of cases without measurable lesions and diffuse uptake of 18FDG in the liver is required;
- •Age ≥18 years old, regardless of gender;
- •Whole body physical condition score (ECOG) 0-2;
- •Expected survival time>3 months;
- •Adequate bone marrow and organ functions;
- •Not accompanied by hemophagocytic syndrome; If the patient is accompanied by clinically diagnosed hemophagocytic syndrome, after targeted anti hemophagocytic syndrome drug treatment, the researcher evaluates the patient's general physical condition to determine whether they can be enrolled.
- •Volunteer to participate in clinical research and sign an informed consent form, willing to follow and capable of completing all trial procedures.
排除标准
- •Received PI3K inhibitor treatment before enrollment;
- •A history of other primary invasive malignant tumors that have not been relieved or have not been relieved for more than 3 years;
- •Involvement of the central nervous system (meninges or brain parenchyma);
- •Individuals who are known to have allergies to any medication in the study
- •Participated in clinical trials of other drugs within 4 weeks prior to the start of the study;
- •Pregnant or lactating women;
- •Individuals with active infections, excluding fever related to tumor B symptoms;
- •Concomitant diseases and medical history:
- •There are many factors affecting oral medicine (such as inability to swallow, chronic diarrhea and Bowel obstruction);
- •Individuals with a history of abuse of psychotropic substances who are unable to quit or have mental disorders;
- •Subjects with any severe and/or uncontrollable diseases, including:
- •Poor blood pressure control (systolic blood pressure ≥ 150mm Hg or diastolic blood pressure ≥ 100 mmHg);
- •Suffering from ≥ Level 2 myocardial ischemia or infarction, arrhythmia (including QTc ≥ 450ms (male), QTc ≥ 470ms (female)), and ≥ Level 2 congestive heart failure (New York Heart Association (NYHA) classification);
- •Active interstitial pneumonia or other chronic lung diseases, leading to severe impairment of lung function, defined as FEV1 and DLCOc<60% of normal predicted values; A history of interstitial pneumonia caused by COVID-
- •Liver abnormalities:
- •I. Decompensated cirrhosis (Child Pugh liver function rating of B or C) II Known clinically significant history of liver disease. Including viral hepatitis, known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e. HBV DNA positivity (>2500 copies/mL or>500IU/mL, and greater than the upper limit of normal values); Known hepatitis C virus infection (HCV) and HCV RNA positivity (>1 × 103 copies/mL). Note: hepatitis B HBsAg positive subjects who meet the inclusion conditions, whether their HBV DNA is measurable or not, need to continue antiviral treatment (nucleoside analogues are recommended) and regularly monitor HBV DNA; For subjects with positive HBcAb but negative HBsAg in hepatitis B, HBV DNA should be monitored regularly and preventive antiviral treatment should be recommended; Hepatitis C patients need to regularly monitor HCV RNA.
- •Renal failure requiring hemodialysis or Peritoneal dialysis;
- •Subjects with uncontrolled Pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
- •Poor control of diabetes (Fasting blood sugar (FBG)>10mmol/L);
- •Urinary routine examination indicates that urine protein is ≥++, and it is confirmed that 24-hour urine protein quantification is greater than 1.0 g;
- •. Have a history of immune deficiency, including positive Diagnosis of HIV/AIDS, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation;
- •. According to the judgment of the researcher, there are serious accompanying diseases that pose a serious threat to the patient's safety or affect the patient's ability to complete the study.
研究组 & 干预措施
Linperlisib in combination with CHOP
Experimental
Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.
干预措施: Linperlisib in combination with CHOP (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT, Phase Ib)
时间窗: The first cycle of linperlisib in combination with R-CHOP regimen (21 days)
To identify the DLT
Complete remission rate (CR rate) based on the 2014 Lugano evaluation criteria (Phase II)
时间窗: Up to 18 weeks
To investigate the antitumor efficacy
次要结局
- Overall response rate (ORR)(Up to 18 weeks)
- Duration of complete remission(From date of complete remission to the study treatment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
- Progression free survival (PFS)(From date of the first injection until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
- Overall survival (OS)(From date of the first injection until the date of death from ant cause, assessed up to 24 months)
- Incidence and severity of adverse events (AE) and Serious adverse event (SAE), as well as abnormal laboratory inspection indicators; Quality of Life (QOL).(Through study completion, an average of 2 years)
- Duration of remission (DOR)(From date of remission to the study treatment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)
研究者
Qingqing Cai
Chief physician
Sun Yat-sen University
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)Nodal T-follicular Helper Cell LymphomaNCT06347653Peking University54
Unknown
2 期
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaPeripheral T/NK Cell Lymphoma (R/R PTCL)NCT05274997Shanghai YingLi Pharmaceutical Co. Ltd.97
终止
1 期
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerBreast CancerNCT02561832AstraZeneca15
已完成
1 期
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.Advanced Solid TumoursNCT02430311AstraZeneca36
招募中
2 期
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)Diffuse Large B Cell LymphomaNCT06517511Sun Yat-sen University42